Brean Capital Sees No Surprises In 3Q14 Report For Repros Therapeutics
November 11, 2014 at 10:28 AM EST
In a report published Tuesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and $41.00 price target on Repros ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.